



# Pertussis vaccines and protective immunity

Parul Kapil and Tod J Merkel

Despite high vaccine coverage, reported cases of pertussis have increased steadily over the last twenty years. This resurgence has stimulated interest in host responses to pertussis infection and vaccination with the goal of developing more effective next-generation vaccines and vaccination strategies. Optimal protection against *Bordetella pertussis* appears to be multifactorial requiring both humoral and cellular responses. Natural infection and whole-cell pertussis vaccination induce Th1 and Th17-dominated responses. In contrast, acellular vaccines induce Th2-dominated responses. Available immunological data indicate that while antibodies provide protection against disease, Th1 and Th17-mediated immune responses are required for bacterial clearance and long-lasting protection. The nature of the priming in children appears to be important in modulating bias and durability of immune responses required to provide protection against *B. pertussis*. This review summarizes the current understanding of differences in immune responses and their role in protection against *B. pertussis* following infection or vaccination.

## Address

Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Silver Spring MD 20993, USA

Corresponding author: Merkel, Tod J ([tod.merkel@fda.hhs.gov](mailto:tod.merkel@fda.hhs.gov))

Current Opinion in Immunology 2019, 59:72–78

This review comes from a themed issue on **Vaccines**

Edited by **Shane Crotty**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 9th May 2019

<https://doi.org/10.1016/j.coi.2019.03.006>

0952-7915/Published by Elsevier Ltd.

## Introduction

Pertussis is an acute respiratory disease caused by the bacterium *Bordetella pertussis*. The disease is characterized by violent coughing fits associated with an inspiratory whoop and post-tussive vomiting [1,2]. Because the first routine pertussis vaccination occurs at six to eight weeks of age, infants under two months of age are the most vulnerable and have the highest rate of serious clinical complications requiring hospitalization and the highest mortality rate [3,4]. Disease in very young infants is characterized by gagging, gasping, bradycardia, cyanosis, and vomiting [5]. Apneic episodes following paroxysmal fits are common [5]. Severe and fatal pertussis in

young infants is associated with extreme leukocytosis, pulmonary hypertension, and pneumonia [5,6].

In the pre-vaccine era there were an average of 162 000 cases of pertussis per year (151 cases/100 000) in the United States with an average case fatality rate of 4% (1926 and 1929 Annual Reports of the Surgeon General of the Public Health Service of the United States). Introduction of killed, whole-cell pertussis (wP) vaccines combined with diphtheria and tetanus antigens (DTwP) in the 1940s led to a rapid decline in the incidence of reported pertussis resulting in a historic low of only 1010 cases in 1976 [7]. However, the wP vaccine was commonly associated with mild injection site pain and swelling, low-grade fever and fretfulness and less commonly with more severe reactions: convulsions and hypotonic–hyporesponsive episodes [8–11]. This reactogenicity led to reduced acceptance of the wP vaccine and declining vaccination rates in most industrialized countries [12]. In response to these concerns, less reactogenic acellular pertussis (aP) vaccines were developed consisting of purified *B. pertussis* antigens combined with aluminum adjuvant. Clinical trials confirmed aP vaccines were less reactogenic than the wP vaccines they replaced and demonstrated comparable efficacy over the first five years following vaccination [11,13–16]. High-income countries began replacing combined DTwP vaccines with combination DTaP vaccines in the 1990s. Under the currently recommended vaccination schedule in the United States, children receive the DTaP vaccine at two, four and six months of age and booster doses at 15–18 months of age, 4–6 years of age and Tdap at 11–12 years of age [17]. Approximately 95% of children receive at least three doses of vaccine by school entry and greater than 80% of children receive the adolescent booster dose by middle school enrollment [18,19]. Despite these high rates of vaccination, the United States has experienced a steady increase in reported cases of pertussis since 2000 (CDC, Pertussis Surveillance and Reporting website; URL: <http://www.cdc.gov/pertussis/surv-reporting.html>). Several hypotheses have been proposed to explain this resurgence including more rapid waning of protective immunity following aP vaccination, evolution of *B. pertussis* to escape protective vaccine-mediated immunity, and increased carriage and asymptomatic transmission from individuals vaccinated with the aP vaccines [20,21\*\*]. In this review, we summarize the current understanding of the host immune response to pertussis infection and vaccination.

## Immune correlates and protection

Over one hundred years after Bordet and Gengou identified *B. pertussis* as the causative agent of whooping cough, we still lack a complete understanding of how the bacterium causes

disease or the mechanisms by which host immunity to infection or vaccination confers protection. Studies conducted during the whole-cell vaccine era had shown a correlation between measurable agglutinin titers in serum with protection against pertussis [22–24]. However, large field clinical studies that demonstrated efficacy of the aP vaccines, failed to demonstrate correlation between protection and antibody titers for any of the vaccine antigens [25]. Evidence for antibody-mediated protection was subsequently provided in household contact studies in which pre-exposure antibody levels were evaluated for cases of pertussis that occurred in two of the large efficacy trials [26,27]. In these household contact studies, lower attack rates were observed in children with high pre-exposure levels of anti-pertactin (PRN) antibodies, anti-fimbriae (FIM) antibodies, and to a lesser extent anti-pertussis toxin (PT) antibodies. The lowest attack rates were seen in children with quantifiable antibodies against both pertactin and fimbriae, independent of the presence or absence of anti-PT antibodies. There was no observable contribution of anti-filamentous hemeagglutinin (FHA) levels to protection [28,29]. Evidence that antibodies alone can confer protection from disease was provided by mouse studies in which high titer anti-pertussis human immunoglobulin and mouse anti-PT monoclonal antibodies protected mice from pertussis challenge even when given seven days after challenge [30,31]. Additional evidence includes recent studies demonstrating that vaccination of pregnant baboons with aP vaccine or mono-component PT vaccine protected newborn baboons from challenge and retrospective studies demonstrating protection in newborn children born to mothers that received Tdap in pregnancy [32–34,35,36,37,38]. The protection documented in these studies is reasonably assumed to be due to the trans-placental transfer of antibodies from mothers to their infants. The lack of a strong correlation between serum antibody titers and protection in the vaccine efficacy studies suggests that cell-mediated immunity and/or mucosal immunity plays an important role in establishing protective immunity (Figure 1).

### Natural immunity

The complex etiology of *B. pertussis* is attributed to expression of multiple virulence factors that contribute directly to pathogenesis or have immunomodulatory effects. The interface between innate and adaptive immune responses is key to the recognition of *B. pertussis* and the control of the infection by the host response. The recognition of bacterial antigens by receptors on mucosal epithelial cells and innate immune cells such as macrophages and dendritic cells leads to activation of a cascade of immune responses including both pro-inflammatory (IL6, IL1 $\beta$ , TNF $\alpha$ , IL8, IL12, IL23, and IFN type 1) and anti-inflammatory (IL10) responses [39–44]. B cells and CD4 T cells were identified as the main effector cells in providing protection against *B. pertussis* infections [45,46]. It was further demonstrated that in addition to their role in antibody production, CD4 T cells provide protection


against *B. pertussis* through an antibody independent mechanism [45]. Initial investigations of cytokine production by peripheral blood T cells from children recovering from whooping cough indicated that immunity generated by natural infection is mediated by IFN $\gamma$  producing T cells [47]. Evidence of the relevance of these cells is provided by the observation that memory CD4 T cells clones generated from PBMCs of previously infected adults secrete IFN $\gamma$ , induce anti-microbial activity in phagocytic cells and provide help to opsonizing B cells [48]. The direct role of CD4 T cells in bacterial clearance was demonstrated by adoptive transfer from wild-type mice into immunocompromised mice [49]. Taken together, these results suggest CD4 T cells contribute to protection from *B. pertussis* colonization through IFN $\gamma$ -dependent mechanisms. Recent advances in the evaluation of Th17 responses have extended our understanding of the cellular immune response to pertussis infection. The production of the Th17-promoting cytokine IL23 by *B. pertussis*-infected human dendritic cells suggested a role for Th17 cells in anti-pertussis immunity [50]. The detection of IL17 production in murine and baboon airways following *B. pertussis* infection and the inability of IL17A receptor knock out mice to clear *B. pertussis* infection demonstrated the importance of the Th17 response to protection following *B. pertussis* infection [51,52]. Further evidence of the relevance of Th1 and Th17 responses against *B. pertussis* infection and colonization was provided by the baboon model [53,54]. Following infection with *B. pertussis*, baboons exhibited strong Th1 and Th17 responses, that resulted in protection from clinical signs of disease and sterilizing immunity [21,52].

In addition to the proposed role of *B. pertussis*-specific IFN $\gamma$  and/or IL17 responses in clearance of bacteria from the airway, the induction of IFN $\gamma$  and/or IL17 producing tissue resident memory T cells observed in mouse lungs following infection has been shown to play a significant role in providing long-term memory following *B. pertussis* infection in the mouse model [55].

### Vaccine-mediated immunity

The temporal association of the switch from wP to aP vaccines with the resurgence of pertussis, combined with our expanding understanding of differences in aP and wP-induced immunity, is consistent with the hypothesis that the observed resurgence is the result of the switch from wP to aP vaccines. Comparative studies demonstrated that both wP and aP vaccines induce strong IgG responses against pertussis antigens. aP vaccines, which are formulated with a single adjuvant and a limited set of antigens, stimulate a different and more restricted immune response profile compared to wP vaccines or natural infection. Both wP vaccines and infection present a broad array of antigens and potential adjuvants. Infection also presents the signals associated with the replication of

Figure 1



Host immune response to pertussis infection and vaccination.

bacterial cells and host damage at the mucosal surface. Infants primed with aP or wP vaccines exhibit differences in the polarization of the immune response between Th1, Th2 and Th17 as shown by the *B. pertussis*-specific IgG subclass distribution observed at 4–10 years of age [56<sup>••</sup>,57<sup>••</sup>]. In children primed with wP vaccines IgG4 levels remained low despite receiving a DTaP booster at 4 and 9 years of age [56<sup>••</sup>,57<sup>••</sup>]. Increased levels of the IgG4 subclass are associated with a Th2-skewed immune response, which may influence the protection against pertussis in vaccinated children [58]. A recent study comparing the immune response between wP and aP primed individuals revealed that CD4 T cells from wP primed individuals produced high levels of PT-specific IFN $\gamma$  and IL17, but no IL4, whereas CD4 T cells from aP primed individuals expressed high levels of IL4, but no IFN $\gamma$  or IL17. CD4 T cells from wP primed individuals remained committed to their original skewing following boosting with aP vaccine, continuing to produce high levels of IFN $\gamma$  and IL17, but no IL4 [59<sup>••</sup>]. Moreover, wP primed individuals exhibited greater expansion of pertussis-specific CD4 T effector memory and T central memory responses, and IgG and IgG1 responses, than aP primed individuals after an aP boost [59<sup>••</sup>]. Taken together these studies illustrate the importance of the priming vaccine in programming the immune response. The clinical significance of the priming vaccine was demonstrated by the observation that among 11–12-year-old children born during the transition from wP vaccine to aP vaccine in Queensland Australia, those who received only aP vaccine had the highest rates of pertussis, while those who received only wP vaccine had the lowest incidence. Of those individuals that received a mixed course of vaccination, those that received a first dose of aP followed by wP had high incidence of disease while those that had an initial dose of wP followed by aP had low incidence of disease [60].

The relative contribution of Th1, Th2 and Th17 cellular responses to vaccine-mediated protection differs to some degree depending on species. In mice, aP vaccination induces CD4<sup>+</sup> T cells to produce IL4, IL5, IL17, and to lesser extent IFN $\gamma$ , consistent with the induction of a Th2/Th17 response [51<sup>••</sup>,61<sup>••</sup>]. In contrast, wP vaccines induce IFN $\gamma$  and IL17A in mice consistent with the induction of a Th1/Th17 response [51<sup>••</sup>]. Although IL4 and IFN $\gamma$  expression is induced by aP vaccine in mice, aP-mediated protection was comparable in IL4<sup>-/-</sup>, IFN $\gamma$ <sup>-/-</sup> and wild-type mice. In contrast, aP-mediated protection was significantly reduced in IL17A<sup>-/-</sup> mice indicating a required role for Th17 responses in vaccine-induced protection [51<sup>••</sup>]. Protection against infection following wP vaccination was greatly diminished in IFN $\gamma$ <sup>-/-</sup> mice with significantly higher bacterial burden in the lungs that failed to clear. Bacterial burdens in wP-vaccinated IL17A<sup>-/-</sup> mice are somewhat higher early after infection but the infection cleared as rapidly as in

wild-type mice. These results indicate that Th1 responses are required for the protection induced with wP vaccines in mice [51<sup>••</sup>,62].

In the baboon model, vaccination with wP vaccines induced strong Th1 and Th17 responses but no Th2 response. Baboons vaccinated with wP vaccine were protected from disease and rapidly cleared infection [21<sup>••</sup>,63]. In contrast, vaccination with aP vaccines resulted in strong Th2 responses, low Th1 responses and no Th17 responses [21<sup>••</sup>,63]. Immunization with aP vaccines conferred protection against disease but failed to prevent colonization, carriage or transmission to co-housed animals [21<sup>••</sup>,63]. Taken together, these results indicate that Th2 responses are sufficient to protect against disease and Th1 and/or Th17 cells are required for the prevention of *B. pertussis* colonization in the baboon model.

Analysis of cellular responses in blood samples from children following immunization with wP vaccine or following infection revealed moderate to high levels of IFN $\gamma$ , but undetectable IL5. In contrast, blood samples from children following immunization with aP vaccine demonstrated high levels of IL5 and low levels of IFN $\gamma$  [64–67]. These results indicate that aP vaccination induces strong Th2 responses and weak Th1 responses in humans while wP vaccines induce strong Th1 responses. These results mirror those observed in the baboon model. Direct evidence of induction of Th17 responses following the priming series of vaccination in children is lacking. However, a recent study demonstrated high levels of IFN $\gamma$  and IL17 but no IL4 following aP boosting of wP-primed children [59<sup>••</sup>]. In contrast, only IL4 was induced following aP boosting of aP-primed children [59<sup>••</sup>].

## Immune memory

Although markers that correlate with duration of immunity following vaccination have not been identified and are difficult to validate, an important determinant of long-term immunity may be the induction of tissue resident memory (Trm) cells [68]. It was recently shown that *B. pertussis* infection establishes CD4<sup>+</sup> Trm cells in lungs of infected animals [55<sup>••</sup>]. These cells expanded rapidly in the lung tissue upon re-infection and provided a protective response [55<sup>••</sup>]. The importance of Trm cells in protection upon reinfection was demonstrated by blocking the influx of lymphocytes upon reinfection and through adoptive transfer studies [55<sup>••</sup>]. Additionally, an experimental acellular pertussis vaccine adjuvanted to stimulate Th1 and Th17 responses induced *B. pertussis*-specific Trm cells in the lungs of vaccinated mice and conferred protection against infection that persisted for ten months [69<sup>••</sup>]. The protection observed in this study correlated with the number of IL17-secreting Trm cells in nasal tissue.

## Conclusion

The observed rates of pertussis in high-income countries despite high rates of vaccination highlight the need for new vaccines or vaccine strategies to achieve complete control of this disease. The available evidence suggests that Th2 responses are likely sufficient to protect against disease. However, Th1 responses and/or Th17 responses targeting the bacterial cell at the mucosal surface are required to mediate clearance of bacteria from the airway and prevent asymptomatic carriage. Studies in the mouse and baboon models have shown that infection induces strong immune responses that prevent disease and result in sterilizing immunity. Killed whole-cell vaccines stimulate an immune profile similar to infection and protect against disease and colonization. Although wP vaccines do not induce sterilizing immunity, wP-vaccinated baboons were colonized at significantly reduced levels and cleared infection quickly. Although aP vaccines protect against disease, they fail to prevent carriage in and transmission from vaccinated baboons. If this observation is relevant in people, it is reasonable to hypothesize that increased asymptomatic carriage would be observed in an aP-vaccinated population leading to increased pertussis exposure in that population. Data indicate that the duration of immunity induced by aP vaccines is shorter than that induced by wP vaccines, and priming by aP vaccines in infants appears to lead to diminished duration of immunity following subsequent boosting in adolescence [70]. Despite these shortcomings, it is important to recognize that aP vaccines were developed in response to a significant need as acceptance of wP vaccination fell in high-income countries. The licensed aP vaccines have an excellent safety profile and protect vaccinated individuals from disease. With the implementation of maternal vaccination to protect newborns in their first months of life and vaccination of infants and toddlers, we can prevent severe disease in young children using the existing vaccines [71]. A comparison of pertussis rates in high-income countries today with rates in the pre-vaccine era demonstrates that we are maintaining significant levels of control of pertussis. However, pertussis remains the most common vaccine-preventable disease. Next-generation vaccines are needed that combine the safety profile and protection against disease inherent in the aP vaccines with protection against colonization and enhanced duration of immunity. A number of new approaches are being taken toward this goal. These include the development of improved aP vaccines that incorporate alternative adjuvants and antigens to induce more durable immunity and target the bacterial cell for clearance, aP vaccines based on outer membrane vesicles, live-attenuated pertussis vaccine and killed whole-cell vaccines using genetically engineered strains designed to be less reactogenic [72]. As we work toward the goal of introducing next-generation pertussis vaccines, it is important to recognize that our understanding of the host-response to pertussis infection and vaccination is incomplete. Continued efforts using

powerful tools available in the mouse model and proof of concept studies with novel vaccines in the baboon model are needed to understand the mechanisms underlying vaccine-mediated protection against pertussis.

## Conflict of interest statement

Nothing declared.

## Acknowledgements

We thank Drusilla Burns, Manuel Osorio, and Tracy Nicholson for critical reading of the manuscript. The authors' research program is funded by the U.S. Food and Drug Administration and supported by NIH/NIAID through interagency agreement (the National Institutes of Health) Y1-AI-1727-01Y1-AI-1727-01.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ: **Pertussis: microbiology, disease, treatment, and prevention.** *Clin Microbiol Rev* 2016, **29**:449-486.
2. Pinto MV, Merkel TJ: **Pertussis disease and transmission and host responses: insights from the baboon model of pertussis.** *J Infect* 2017, **74**(Suppl. 1):S114-S119.
3. Chu HY, Englund JA: **Maternal immunization.** *Clin Infect Dis* 2014, **59**:560-568.
4. Lindsey B, Kampmann B, Jones C: **Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants.** *Curr Opin Infect Dis* 2013, **26**:248-253.
5. Cherry JD: **Pertussis in young infants throughout the world.** *Clin Infect Dis* 2016, **63**:S119-S122.
6. Murray EL, Nieves D, Bradley JS, Gargas J, Mason WH, Lehman D, Harriman K, Cherry JD: **Characteristics of severe *Bordetella pertussis* infection among infants <=90 days of age admitted to pediatric intensive care units - Southern California, September 2009-June 2011.** *J Pediatric Infect Dis Soc* 2013, **2**:1-6.
7. Klein NP: **Licensed pertussis vaccines in the United States. History and current state.** *Hum Vaccin Immunother* 2014, **10**:2684-2690.
8. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR: **Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.** *Pediatrics* 1981, **68**:650-660.
9. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF: **Comparison of 13 acellular pertussis vaccines: adverse reactions.** *Pediatrics* 1995, **96**:557-566.
10. Englund JA, Glezen WP, Barreto L: **Controlled study of a new five-component acellular pertussis vaccine in adults and young children.** *J Infect Dis* 1992, **166**:1436-1441.
11. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J: **A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.** *N Engl J Med* 1996, **334**:349-355.
12. Plotkin SA: **The pertussis problem.** *Clin Infect Dis* 2014, **58**:830-833.
13. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC et al.: **A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.** *N Engl J Med* 1996, **334**:341-348.

14. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H: **Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.** *Lancet* 1997, **350**:1569-1577.
15. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, Sanden G, Mboup S, Hoffenbach A, Knudsen K *et al.*: **A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.** *Vaccine* 1997, **15**:1606-1612.
16. Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB: **A placebo-controlled trial of a pertussis-toxoid vaccine.** *N Engl J Med* 1995, **333**:1045-1050.
17. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA: **Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP).** *Morb Mortal Wkly Rep* 2018, **67**:1-44.
18. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y: **Vaccination coverage among children aged 19-35 months - United States, 2017.** *MMWR Morb Mortal Wkly Rep* 2018, **67**:1123-1128.
19. Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S: **National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016.** *MMWR Morb Mortal Wkly Rep* 2017, **66**:874-882.
20. Althouse BM, Scarpino SV: **Asymptomatic transmission and the resurgence of *Bordetella pertussis*.** *BMC Med* 2015, **13**:146.  
This study demonstrated that increased asymptomatic transmission from aP-vaccinated individuals is sufficient to account for the resurgence of *B. pertussis* in the US and UK.
21. Warfel JM, Zimmerman LI, Merkel TJ: **Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.** *Proc Natl Acad Sci U S A* 2014, **111**:787-792.  
This study distinguished between infection and disease and demonstrated that the aP vaccines did not prevent bacterial colonization, carriage and transmission in a baboon.
22. Miller JJ, Silverberg RJ, Saito TM, Humber JB: **An agglutinative reaction for *Hemophilus pertussis*: II. Its relation to clinical immunity.** *J Pediatr* 1943, **22**:644-651.
23. Sako W: **Studies on pertussis immunization.** *J Pediatr* 1947, **30**:29-40.
24. Council MR: **Vaccination against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley.** *Br Med J* 1956, **2**:454-462.
25. Vaccines AHGTSOP: **Placebo-controlled trial of two acellular pertussis vaccines in Sweden - Protective efficacy and adverse events.** *Lancet* 1988, **331**:955-960.
26. Cherry JD, Gornbein J, Heininger U, Stehr K: **A search for serologic correlates of immunity to *Bordetella pertussis* cough illnesses.** *Vaccine* 1998, **16**:1901-1906.  
This study provided evidence of antibody-mediated protection following vaccination.
27. Storsaeter J, Hallander HO, Gustafsson L, Olin P: **Levels of anti-pertussis antibodies related to protection after household exposure to *Bordetella pertussis*.** *Vaccine* 1998, **16**:1907-1916.  
This study provided evidence of antibody-mediated protection following vaccination.
28. Hewlett EL, Halperin SA: **Serological correlates of immunity to *Bordetella pertussis*.** *Vaccine* 1998, **16**:1899-1900.
29. Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J: **How to make sense of pertussis immunogenicity data.** *Clin Infect Dis* 2001, **33**(Suppl. 4):S288-291.
30. Sato H, Sato Y: **Protective activities in mice of monoclonal antibodies against pertussis toxin.** *Infect Immun* 1990, **58**:3369-3374.  
This study demonstrated that anti-pertussis toxin antibody was sufficient to provide protection against *B. pertussis* disease in the mouse model.
31. Bruss JB, Siber GR: **Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.** *Clin Diagn Lab Immunol* 1999, **6**:464-470.  
This study demonstrated that high-titer human polyclonal serum raised against pertussis toxoid antibody was sufficient to provide protection against *B. pertussis* disease in the mouse model.
32. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M: **Effectiveness of maternal pertussis vaccination in England: an observational study.** *Lancet* 2014, **384**:1521-1528.
33. Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, Andrews N: **Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction.** *Clin Infect Dis* 2016, **63**:S236-S243.
34. Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP: **Effectiveness of vaccination during pregnancy to prevent infant pertussis.** *Pediatrics* 2017, **139**.
35. Kapil P, Papin JF, Wolf RF, Zimmerman LI, Wagner LD, Merkel TJ: **Maternal vaccination with a mono-component pertussis toxoid vaccine is sufficient to protect infants in a baboon model of whooping cough.** *J Infect Dis* 2018, **217**:1231-1236.  
This study showed that maternal vaccination with pertussis toxoid was sufficient to protect infant baboons from pertussis providing evidence of antibody-mediated protection in baboons.
36. Warfel JM, Papin JF, Wolf RF, Zimmerman LI, Merkel TJ: **Maternal and neonatal vaccination protects newborn baboons from pertussis infection.** *J Infect Dis* 2014, **210**:604-610.
37. Winter K, Cherry JD, Harriman K: **Effectiveness of prenatal tetanus, diphtheria, and acellular pertussis vaccination on pertussis severity in infants.** *Clin Infect Dis* 2017, **64**:9-14.
38. Winter K, Nickell S, Powell M, Harriman K: **Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis.** *Clin Infect Dis* 2017, **64**:3-8.  
This study demonstrated that Tdap vaccination at 27-36 weeks of gestation is 85% effective in preventing pertussis in infants <8 weeks of age compared to postpartum vaccination. This provides evidence of anti-body-mediated protection in humans.
39. Carbonetti NH: **Immunomodulation in the pathogenesis of *Bordetella pertussis* infection and disease.** *Curr Opin Pharmacol* 2007, **7**:272-278.
40. Dieterich C, Relman DA: **Modulation of the host interferon response and ISGylation pathway by *B. pertussis* filamentous hemagglutinin.** *PLoS One* 2011, **6**:e27535.
41. Fedele G, Bianco M, Debie AS, Loch C, Ausiello CM: **Attenuated *Bordetella pertussis* vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.** *J Immunol* 2011, **186**:5388-5396.
42. Fedele G, Celestino I, Spensieri F, Frasca L, Nasso M, Watanabe M, Remoli ME, Coccia EM, Altieri F, Ausiello CM: **Lipooligosaccharide from *Bordetella pertussis* induces mature human monocyte-derived dendritic cells and drives a Th2 biased response.** *Microbes Infect* 2007, **9**:855-863.
43. Ausiello CM, Fedele G, Urbani F, Lande R, Di Carlo B, Cassone A: **Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses.** *J Infect Dis* 2002, **186**:351-360.
44. Trinchieri G, Pflanz S, Kastelein RA: **The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses.** *Immunity* 2003, **19**:641-644.
45. Leef M, Elkins KL, Barbic J, Shahin RD: **Protective immunity to *Bordetella pertussis* requires both B cells and CD4(+) T cells for key functions other than specific antibody production.** *J Exp Med* 2000, **191**:1841-1852.

46. Barbic J, Leef MF, Burns DL, Shahin RD: **Role of gamma interferon in natural clearance of *Bordetella pertussis* infection.** *Infect Immun* 1997, **65**:4904-4908.
47. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH: ***Bordetella pertussis* respiratory infection in children is associated with preferential activation of type 1 T helper cells.** *J Infect Dis* 1997, **175**:1246-1250.
48. Peppoloni S, Nencioni L, Di Tommaso A, Tagliabue A, Parronchi P, Romagnani S, Rappuoli R, De Magistris MT: **Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against *Bordetella pertussis*.** *Infect Immun* 1991, **59**:3768-3773.  
 This study evaluated the role of memory CD4 T cells clone generated from PBMCs isolated from previously infected adults. These CD4 T cell clones secreted IFN $\gamma$ , and provided help in inducing anti-microbial activity of phagocytic cells and to opsonizing B cells.
49. Mills KH, Barnard A, Watkins J, Redhead K: **Cell-mediated immunity to *Bordetella pertussis*: role of Th1 cells in bacterial clearance in a murine respiratory infection model.** *Infect Immun* 1993, **61**:399-410.  
 This study identified the importance of antigen-specific CD4 T cells in bacterial clearance following *B. pertussis* challenge in mice.
50. Fedele G, Stefanelli P, Spensieri F, Fazio C, Mastrantonio P, Ausiello CM: ***Bordetella pertussis*-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression.** *Infect Immun* 2005, **73**:1590-1597.  
 This study demonstrated that infection with *B. pertussis* induces the secretion of IL23 in macrophage derived dendritic cells.
51. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH: **Relative contribution of Th1 and Th17 cells in adaptive immunity to *Bordetella pertussis*: towards the rational design of an improved acellular pertussis vaccine.** *PLoS Pathog* 2013, **9**:e1003264.  
 This study established role of Th1 and Th17 cells in bacterial clearance after *B. pertussis* infection or after immunization with either wP or aP.
52. Warfel JM, Merkel TJ: ***Bordetella pertussis* infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates.** *Mucosal Immunol* 2013, **6**:787-796.  
 This study verified that *B. pertussis* infection induces IL17 production as local response and Th1 and Th17 memory cells as systemic response in non-human primates.
53. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ: **Nonhuman primate model of pertussis.** *Infect Immun* 2012, **80**:1530-1536.
54. Warfel JM, Merkel TJ: **The baboon model of pertussis: effective use and lessons for pertussis vaccines.** *Expert Rev Vaccines* 2014, **13**:1241-1252.
55. Wilk MM, Misiak A, McManus RM, Allen AC, Lynch MA, Mills KHG: **Lung CD4 tissue-resident memory T cells mediate adaptive immunity induced by previous infection of mice with *Bordetella pertussis*.** *J Immunol* 2017, **199**:233-243.  
 This study demonstrated that CD4 resident memory T cells accumulate in lungs following *B. pertussis* infection, expand significantly following reinfection and provide protection against *B. pertussis* infection in naïve mice when adoptively transferred.
56. van der Lee S, Hendriks LH, Sanders EAM, Berbers GAM, Buisman AM: **Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles.** *Front Immunol* 2018, **9**:51.  
 This study demonstrated that memory immune response determined by primary vaccination series during infancy with either wP or aP vaccine can not be readily reprogrammed by boosting with Tdap.
57. van der Lee S, Sanders EAM, Berbers GAM, Buisman AM: **Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.** *Vaccine* 2018, **36**:220-226.  
 This study demonstrated that primary immunization series with either DTwP or DTaP determined the profile of antigen specific IgG subclass in children and these profile did not change after booster vaccination with DTaP.
58. Aalberse RC, Stapel SO, Schuurman J, Rispens T: **Immunoglobulin G4: an odd antibody.** *Clin Exp Allergy* 2009, **39**:469-477.
59. da Silva Antunes R, Babor M, Carpenter C, Khalil N, Cortese M, Mentzer AJ, Seumois G, Petro CD, Purcell LA, Vijayanand P et al.: **Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.** *J Clin Invest* 2018, **128**:3853-3865.  
 This study verified that fate of CD4 T cells established by childhood priming with either wP or aP vaccine remains committed despite boosting with aP vaccine.
60. Sheridan SL, Ware RS, Grimwood K, Lambert SB: **Number and order of whole cell pertussis vaccines in infancy and disease protection.** *JAMA* 2012, **308**:454-456.
61. Brummelman J, Wilk MM, Han WG, van Els CA, Mills KH: **Roads to the development of improved pertussis vaccines paved by immunology.** *Pathog Dis* 2015, **73**:ftv067.  
 This report demonstrated that children primed with DTwP vaccine were better protected against *B. pertussis* infection than children primed with only DTaP vaccine following exposures approximately 10 years following primary vaccination.
62. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH: **TLR4 mediates vaccine-induced protective cellular immunity to *Bordetella pertussis*: role of IL-17-producing T cells.** *J Immunol* 2006, **177**:7980-7989.
63. Warfel JM, Zimmerman LI, Merkel TJ: **Comparison of three whole-cell pertussis vaccines in the baboon model of pertussis.** *Clin Vaccine Immunol* 2015, **23**:47-54.
64. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Loch C: **Modulation of the infant immune responses by the first pertussis vaccine administrations.** *Vaccine* 2007, **25**:391-398.
65. Mascart F, Verscheure V, Malfroot A, Hainaut M, Pierard D, Temerman S, Peltier A, Debie AS, Levy J, Del Giudice G et al.: ***Bordetella pertussis* infection in 2-month-old infants promotes type 1 T cell responses.** *J Immunol* 2003, **170**:1504-1509.
66. Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH: **Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.** *Clin Exp Immunol* 2000, **121**:193-200.
67. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L, Oymar K, Miller E, Storsaeter J, Mills KH: **Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.** *Immunology* 1998, **93**:1-10.
68. Masopust D, Soerens AG: **Tissue-resident T cells and other resident leukocytes.** *Annu Rev Immunol* 2019 <http://dx.doi.org/10.1146/annurev-immunol-042617-053214>. [Epub ahead of print].
69. Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG: **Sustained protective immunity against *Bordetella pertussis* nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells.** *Mucosal Immunol* 2018, **11**:1763-1776.  
 This study demonstrated that an aP vaccine adjuvanted to induce Th1/Th17 producing *B. pertussis*-specific lung T resident memory cells provided long-term protection in a mouse model.
70. Martinon-Torres F, Heininger U, Thomson A, Wirsing von Konig CH: **Controlling pertussis: how can we do it? A focus on immunization.** *Expert Rev Vaccines* 2018, **17**:289-297.
71. Campbell H, Gupta S, Dolan GP, Kapadia SJ, Kumar Singh A, Andrews N, Amirthalingam G: **Review of vaccination in pregnancy to prevent pertussis in early infancy.** *J Med Microbiol* 2018, **67**:1426-1456.
72. Loch C: **Will we have new pertussis vaccines?** *Vaccine* 2018, **36**:5460-5469.